Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3 - PubMed (original) (raw)
Comparative Study
Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3
I Peter et al. Melanoma Res. 2001 Feb.
Abstract
The mouse melanoma cell lines B16, K1735 and Cloudman S91-M3 (and various sublines) are frequently used as melanoma models. Extensive comparative data of their immunological features are not available. In order to define the immunological profiles of these cell lines, relevant tumour markers were studied. S91-M3 melanoma cells constitutively expressed high levels of major histocompatibility complex (MHC) I, in contrast to K1735-M2 and B16-F1 cells. MHC II expression was restricted to B16-F1 cells following interferon-gamma treatment. Tyrosinase, tyrosinase-related protein-2 and gp100 were detected in B16-F1 and S91-M3 cells, but not in K1735-M2 cells. Constitutive surface expression and secretion of intercellular adhesion molecule-1 was found on S91-M3 cells. No substantial secretion of interleukin-10 could be detected. In contrast, low levels of latent transforming growth factor-beta were found in the cell supernatants of B16-F1 and K1735-M2 cells. The expression pattern of Fas, FasL and FLICE inhibitory protein was comparable in all three cell lines. Thus our findings indicate that each cell line presents a characteristic immunological profile, confirming that B16-F1 is an appropriate murine tumour model for tumours with low levels of MHC I but expressing melanoma-associated antigens. S91-M3 represents a complementary, more immunogenic model. In contrast, K1735-M2 does not seem to be an appropriate model for melanoma.
Similar articles
- Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100.
Schreurs MW, de Boer AJ, Schmidt A, Figdor CG, Adema GJ. Schreurs MW, et al. Melanoma Res. 1997 Dec;7(6):463-70. doi: 10.1097/00008390-199712000-00004. Melanoma Res. 1997. PMID: 9464618 - Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR, Wehrli P, Viard-Leveugle I, Rimoldi D, Cerottini JC, Saurat JH, Tschopp J, French LE. Bullani RR, et al. Melanoma Res. 2002 Jun;12(3):263-70. doi: 10.1097/00008390-200206000-00010. Melanoma Res. 2002. PMID: 12140383 - Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures.
Hofbauer GF, Geertsen R, Laine E, Burg G, Dummer R. Hofbauer GF, et al. Melanoma Res. 2001 Jun;11(3):213-8. doi: 10.1097/00008390-200106000-00002. Melanoma Res. 2001. PMID: 11468509 - In vitro comparison between mouse B16 and human melanoma cell lines of the expression of ICAM-1 induced by cytokines and/or hyperthermia.
Nakayama J, Guan XC, Nakashima M, Mashino T, Hori Y. Nakayama J, et al. J Dermatol. 1997 Jun;24(6):351-60. doi: 10.1111/j.1346-8138.1997.tb02805.x. J Dermatol. 1997. PMID: 9241963 - Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells.
Clifford JL, Petkovich M, Chambon P, Lotan R. Clifford JL, et al. Mol Endocrinol. 1990 Oct;4(10):1546-55. doi: 10.1210/mend-4-10-1546. Mol Endocrinol. 1990. PMID: 2178220
Cited by
- TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
Pearson JRD, Puig-Saenz C, Thomas JE, Hardowar LD, Ahmad M, Wainwright LC, McVicar AM, Brentville VA, Tinsley CJ, Pockley AG, Durrant LG, McArdle SEB. Pearson JRD, et al. Cancer Immunol Immunother. 2024 Jul 2;73(9):178. doi: 10.1007/s00262-024-03770-x. Cancer Immunol Immunother. 2024. PMID: 38954031 Free PMC article. - Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Wu Y, Deng W, McGinley EC, Klinke DJ 2nd. Wu Y, et al. Pigment Cell Melanoma Res. 2017 Mar;30(2):203-218. doi: 10.1111/pcmr.12564. Epub 2017 Mar 7. Pigment Cell Melanoma Res. 2017. PMID: 27930879 Free PMC article. - Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Murakami T, et al. J Exp Med. 2003 Nov 3;198(9):1337-47. doi: 10.1084/jem.20030593. Epub 2003 Oct 27. J Exp Med. 2003. PMID: 14581607 Free PMC article. - Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.
MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR. MacGill RS, et al. Clin Exp Metastasis. 2007;24(7):521-31. doi: 10.1007/s10585-007-9089-3. Epub 2007 Jul 25. Clin Exp Metastasis. 2007. PMID: 17653822 Clinical Trial. - U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.
Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K. Haratani K, et al. J Clin Invest. 2020 Jan 2;130(1):374-388. doi: 10.1172/JCI126598. J Clin Invest. 2020. PMID: 31661465 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous